Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
BeyondSpring Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment, particularly its lead product candidate, Plinabulin, which is designed to enhance the efficacy of chemotherapy. The company operates primarily in the United States and China, leveraging its unique dual-market strategy to capture a broader patient base.
BeyondSpring's business model is centered on the development and commercialization of its proprietary cancer therapies. The company aims to secure partnerships with larger pharmaceutical firms to leverage their distribution networks and expertise in regulatory approvals, which provides a competitive advantage in navigating complex market entry barriers.
Clinical trial results for Plinabulin and other candidates
Regulatory approvals from the FDA or other health authorities
Partnership announcements with larger pharmaceutical companies
Market sentiment around biotech sector performance
Regulatory changes impacting drug approval processes
Technological disruption in cancer treatment methodologies
Emergence of alternative therapies that may outperform Plinabulin
Increased competition from established biotech firms with more resources
High cash burn rate with no current revenue generation
Dependence on external funding for R&D
low - The biotechnology sector is generally less sensitive to economic cycles as healthcare spending tends to be more stable, though funding for R&D can be impacted.
Moderate - Rising interest rates could increase the cost of capital for funding clinical trials and operations, potentially impacting the company's ability to finance its growth.
minimal - The company has a low debt level, which reduces its exposure to credit conditions.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has historically shown significant volatility due to the binary nature of clinical trial outcomes.